Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/125912
Title: | Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma |
Author: | Wilson, Wyndham H. Bromberg, Jacoline E.C. Stetler-Stevenson, Maryalice Steinberg, Seth M. Martin Martin, Lourdes Muñiz, Carmen Sancho, Juan Manuel Caballero García, María Dolores Davidis, Marjan A. Brooimans, Rik A. Sánchez González, Blanca Salar, Antonio González Barca, Eva Ribera, Josep Maria Shovlin, Margaret Filie, Armando Dunleavy, Kieron Mehrling, Thomas Spina, Michele Orfao, Alberto |
Keywords: | Limfomes Citometria de fluxe Lymphomas Flow cytometry |
Issue Date: | Jul-2014 |
Publisher: | Ferrata Storti Foundation |
Abstract: | The benefit of intrathecal therapy and systemic rituximab on the outcome of diffuse large B-cell lymphoma at risk of central nervous system disease is controversial. Furthermore, the effect of intrathecal treatment and rituximab in diffuse large B-cell and Burkitt lymphoma with occult leptomeningeal disease detected by flow cytometry at diagnosis is unknown. Untreated diffuse large B-cell (n=246) and Burkitt (n=80) lymphoma at clinical risk of central nervous system disease and having had pre-treatment cerebrospinal fluid were analyzed by flow cytometry and cytology. Spinal fluid involvement was detected by flow cytometry alone (occult) in 33 (13%) diffuse large B-cell and 9 (11%) Burkitt lymphoma patients, and detected by cytology in 11 (4.5%) and 5 (6%) patients, respectively. Diffuse large B-cell lymphoma with occult spinal fluid involvement had poorer survival (P=0.0001) and freedom from central nervous system relapse (P<0.0001) compared to negative cases. Burkitt lymphoma with occult spinal fluid involvement had an inferior freedom from central nervous system relapse (P=0.026) but not survival. The amount of intrathecal chemotherapy was quantitatively associated with survival in diffuse large B-cell lymphoma with (P=0.02) and without (P=0.001) occult spinal fluid involvement. However, progression of systemic disease and not control of central nervous system disease was the principal cause of treatment failure. In diffuse large B-cell lymphoma, systemic rituximab was associated with improved freedom from central nervous system relapse (P=0.003) but not with survival. Our results suggest that patients at risk of central nervous system disease should be evaluated by flow cytometry and that intrathecal prophylaxis/therapy is beneficial. |
Note: | Reproducció del document publicat a: https://doi.org/10.3324/haematol.2013.101741 |
It is part of: | Haematologica, 2014, vol. 99, num. 7, p. 1228-1235 |
URI: | http://hdl.handle.net/2445/125912 |
Related resource: | https://doi.org/10.3324/haematol.2013.101741 |
ISSN: | 0390-6078 |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
679857.pdf | 552.6 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.